{"id":"once-daily-abc-3tc","safety":{"commonSideEffects":[{"rate":"5-8","effect":"Hypersensitivity reaction (abacavir)"},{"rate":"2-5","effect":"Headache"},{"rate":"2-5","effect":"Nausea"},{"rate":"2-5","effect":"Diarrhea"},{"rate":"2-5","effect":"Fatigue"},{"rate":"<1","effect":"Lactic acidosis (rare)"}]},"_chembl":{"chemblId":"CHEMBL191973","moleculeType":"Small molecule","molecularWeight":"437.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Abacavir (ABC) and lamivudine (3TC) are both NRTIs that inhibit HIV reverse transcriptase by competing with natural nucleosides and causing chain termination during viral DNA synthesis. The once-daily formulation combines these two agents to improve adherence while maintaining suppression of HIV replication. This combination is a backbone component of antiretroviral therapy regimens.","oneSentence":"ABC+3TC is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors (NRTIs) that blocks HIV reverse transcriptase to prevent viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:20.537Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (as part of combination antiretroviral therapy)"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT02951052","phase":"PHASE3","title":"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":618},{"nctId":"NCT05122767","phase":"PHASE1, PHASE2","title":"Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2023-05-24","conditions":"Tuberculosis, HIV","enrollment":92},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT07115368","phase":"PHASE1","title":"Study of GS-1219 in Participants With HIV-1","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2025-08-11","conditions":"HIV-1-infection","enrollment":4},{"nctId":"NCT02470650","phase":"PHASE4","title":"Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive","status":"WITHDRAWN","sponsor":"Juan A. Arnaiz","startDate":"2015-06","conditions":"Patient Compliance, Antiretroviral Therapy Intolerance","enrollment":""},{"nctId":"NCT05193994","phase":"PHASE3","title":"Triumeq in Amyotrophic Lateral Sclerosis","status":"TERMINATED","sponsor":"Macquarie University, Australia","startDate":"2022-02-24","conditions":"Amyotrophic Lateral Sclerosis","enrollment":419},{"nctId":"NCT06428045","phase":"PHASE1","title":"STARLITE for Unresectable High-Grade Gliomas","status":"RECRUITING","sponsor":"University of Miami","startDate":"2025-04-15","conditions":"High Grade Glioma","enrollment":24},{"nctId":"NCT00796263","phase":"PHASE3","title":"Antiretroviral Therapy for Acute and Chronic HIV Infection","status":"RECRUITING","sponsor":"SEARCH Research Foundation","startDate":"2009-05-13","conditions":"Acute HIV Infection, Chronic HIV Infection","enrollment":900},{"nctId":"NCT04012931","phase":"PHASE2","title":"A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-07-18","conditions":"HIV","enrollment":26},{"nctId":"NCT02275780","phase":"PHASE3","title":"Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-12-01","conditions":"HIV-1","enrollment":769},{"nctId":"NCT01059422","phase":"PHASE4","title":"Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients","status":"COMPLETED","sponsor":"Central Institute of Epidemiology, Moscow, Russia","startDate":"2010-10","conditions":"HIV Infections, Tuberculosis","enrollment":10},{"nctId":"NCT00799864","phase":"PHASE2","title":"A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2011-01","conditions":"HIV-1","enrollment":54},{"nctId":"NCT02120352","phase":"PHASE2","title":"A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-04-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":309},{"nctId":"NCT04904406","phase":"PHASE4","title":"Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals","status":"COMPLETED","sponsor":"Thomas Benfield","startDate":"2020-10-22","conditions":"Hiv, HIV Infections, HIV Cardiomyopathy","enrollment":81},{"nctId":"NCT02659761","phase":"PHASE4","title":"Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs","status":"TERMINATED","sponsor":"University College Dublin","startDate":"2016-11","conditions":"Human Immunodeficiency Virus","enrollment":33},{"nctId":"NCT06356740","phase":"PHASE2","title":"Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-09-01","conditions":"Systemic Lupus Erythematosus","enrollment":70},{"nctId":"NCT01910402","phase":"PHASE3","title":"A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2013-08-22","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":499},{"nctId":"NCT01605084","phase":"PHASE3","title":"Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2012-06-30","conditions":"HIV","enrollment":""},{"nctId":"NCT02486133","phase":"PHASE3","title":"Dual Therapy With Boosted Darunavir + Dolutegravir","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-07","conditions":"HIV-Infection","enrollment":269},{"nctId":"NCT03178084","phase":"PHASE3","title":"Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio","status":"COMPLETED","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2014-10-15","conditions":"HIV/AIDS","enrollment":721},{"nctId":"NCT04340388","phase":"PHASE4","title":"Contribution of Dolutegravir to Obesity and Cardiovascular Disease","status":"COMPLETED","sponsor":"Augusta University","startDate":"2020-09-17","conditions":"HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases","enrollment":10},{"nctId":"NCT03760458","phase":"PHASE1, PHASE2","title":"The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-09-09","conditions":"HIV Infections","enrollment":57},{"nctId":"NCT02924389","phase":"PHASE4","title":"Dolutegravir in Reservoirs","status":"TERMINATED","sponsor":"Emory University","startDate":"2016-09","conditions":"HIV","enrollment":22},{"nctId":"NCT02075593","phase":"PHASE3","title":"ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-12-17","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections, Arthralgia","enrollment":4},{"nctId":"NCT05525156","phase":"PHASE2","title":"The Effect of Aspirin on HIV Disease Progression Among HIV- Infected Individuals Initiating Anti- Retroviral Therapy","status":"SUSPENDED","sponsor":"Muhimbili University of Health and Allied Sciences","startDate":"2020-03-02","conditions":"Hiv, Cardiovascular Diseases","enrollment":454},{"nctId":"NCT02607930","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-13","conditions":"HIV-1 Infection","enrollment":631},{"nctId":"NCT02384395","phase":"NA","title":"Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2015-09","conditions":"HIV, Acute HIV Infection","enrollment":40},{"nctId":"NCT00102960","phase":"PHASE3","title":"Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-07","conditions":"HIV Infections","enrollment":377},{"nctId":"NCT00270296","phase":"PHASE2","title":"Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-06","conditions":"HIV Infections","enrollment":730},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT03447873","phase":"PHASE4","title":"Tripe Versus Dual Antiretroviral Therapy in HIV-infected Patients With Virological Suppression (Tridual)","status":"COMPLETED","sponsor":"Hospitales Universitarios Virgen del Rocío","startDate":"2017-06-01","conditions":"HIV Infections","enrollment":153},{"nctId":"NCT03602690","phase":"PHASE2","title":"Evaluation of Third-line cART Regimen in Cambodia (3DICAM)","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2018-10-04","conditions":"HIV/AIDS","enrollment":54},{"nctId":"NCT01352715","phase":"PHASE3","title":"Study of Options for Second-Line Effective Combination Therapy (SELECT)","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-03-13","conditions":"HIV-1 Infection","enrollment":515},{"nctId":"NCT02603107","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-20","conditions":"HIV-1 Infection","enrollment":578},{"nctId":"NCT02603120","phase":"PHASE3","title":"Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-11","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT03284645","phase":"","title":"Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids","status":"COMPLETED","sponsor":"Obafemi Awolowo University","startDate":"2017-12-22","conditions":"Human Immunodeficiency Virus Infection","enrollment":194},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT01641809","phase":"PHASE2","title":"Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2012-08-06","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":244},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT01367236","phase":"PHASE4","title":"Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2013-01","conditions":"HIV, Impaired Cognition","enrollment":60},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT01227824","phase":"PHASE3","title":"A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-10-19","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":828},{"nctId":"NCT01263015","phase":"PHASE3","title":"A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-02-01","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":844},{"nctId":"NCT02509195","phase":"PHASE4","title":"SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2015-08-04","conditions":"HIV","enrollment":40},{"nctId":"NCT00951015","phase":"PHASE2","title":"A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2009-07-30","conditions":"Infection, Human Immunodeficiency Virus","enrollment":208},{"nctId":"NCT01449929","phase":"PHASE3","title":"Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-10-31","conditions":"Infection, Human Immunodeficiency Virus","enrollment":488},{"nctId":"NCT01928407","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts","status":"COMPLETED","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2011-02-23","conditions":"HIV-1 Infection, Immunosuppression-related Infectious Disease","enrollment":120},{"nctId":"NCT02246998","phase":"PHASE4","title":"Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-12-15","conditions":"HIV-1 Infection","enrollment":72},{"nctId":"NCT02556268","phase":"PHASE1","title":"Interaction With HIV Antiretroviral Agents","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-23","conditions":"HIV-DDI","enrollment":40},{"nctId":"NCT01231555","phase":"PHASE2","title":"Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2010-11-18","conditions":"Infection, Human Immunodeficiency Virus","enrollment":23},{"nctId":"NCT01608269","phase":"PHASE4","title":"Nucleoside Switch Pilot for Virologically Controlled HIV Subjects With Decreasing CD4 Cells Who Have Received TDF-based ARV Therapy","status":"COMPLETED","sponsor":"Therapeutic Concepts","startDate":"2010-11","conditions":"HiV1- Positive","enrollment":30},{"nctId":"NCT02159599","phase":"PHASE4","title":"Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2014-07","conditions":"HIV Infection","enrollment":249},{"nctId":"NCT02105987","phase":"PHASE3","title":"A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-04","conditions":"Infection, Human Immunodeficiency Virus","enrollment":555},{"nctId":"NCT01440569","phase":"PHASE3","title":"Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-09","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":314},{"nctId":"NCT02588820","phase":"PHASE3","title":"Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection","status":"UNKNOWN","sponsor":"David Garcia Cinca","startDate":"2016-04","conditions":"HIV Infections","enrollment":15},{"nctId":"NCT01127204","phase":"PHASE2, PHASE3","title":"Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2011-06","conditions":"HIV Infections","enrollment":161},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT01363011","phase":"PHASE3","title":"Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-05","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":106},{"nctId":"NCT01656122","phase":"PHASE2, PHASE3","title":"Abacavir and Lamivudine PK in Children","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2012-07","conditions":"HIV","enrollment":30},{"nctId":"NCT02626923","phase":"","title":"Study of Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in ART-Naive & First Switch Patients","status":"COMPLETED","sponsor":"Nicholaos C Bellos, MD","startDate":"2012-07","conditions":"Drug-induced Hypotension","enrollment":51},{"nctId":"NCT01252940","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-11","conditions":"HIV-1 Infection","enrollment":482},{"nctId":"NCT00038506","phase":"PHASE4","title":"Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2002-03","conditions":"HIV Infection","enrollment":100},{"nctId":"NCT00544128","phase":"PHASE4","title":"Comparison of Epzicom and Truvada for the Initial Once Daily HIV Treatment","status":"COMPLETED","sponsor":"International Medical Center of Japan","startDate":"2007-10","conditions":"HIV Infections","enrollment":109},{"nctId":"NCT00338390","phase":"PHASE3","title":"Study to Evaluate Changes in CD4 on Replacing TDF With ABC or DDI+TDF With ABC+3TC","status":"COMPLETED","sponsor":"Hospital de Granollers","startDate":"2005-04","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT01499199","phase":"PHASE3","title":"A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2012-01","conditions":"Infection, Human Immunodeficiency Virus","enrollment":13},{"nctId":"NCT02285374","phase":"PHASE4","title":"Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity","status":"UNKNOWN","sponsor":"St Stephens Aids Trust","startDate":"2014-11","conditions":"HIV","enrollment":40},{"nctId":"NCT02028676","phase":"PHASE4","title":"Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa","status":"COMPLETED","sponsor":"Medical Research Council","startDate":"2007-03","conditions":"Human Immunodeficiency Virus","enrollment":1206},{"nctId":"NCT01973439","phase":"PHASE1","title":"PENTA15: Pharmacokinetic Study of Once Versus Twice Daily Abacavir in HIV-1 Infected Children Aged 3 to <36 Months","status":"COMPLETED","sponsor":"PENTA Foundation","startDate":"2006-07","conditions":"HIV Infection","enrollment":23},{"nctId":"NCT00234091","phase":"PHASE3","title":"When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-04","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT01102972","phase":"PHASE4","title":"A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-04","conditions":"Infection, Human Immunodeficiency Virus","enrollment":297},{"nctId":"NCT01982396","phase":"PHASE1","title":"Pharmacokinetic (PK) Study of Twice Daily vs Once Daily Lamivudine (3TC) and Abacavir (ABC) as Part of Combination Antiretroviral Therapy (ART) in HIV Infected Children","status":"COMPLETED","sponsor":"PENTA Foundation","startDate":"2003-01","conditions":"HIV Infection","enrollment":19},{"nctId":"NCT00727597","phase":"PHASE3","title":"A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2008-07","conditions":"Human Immunodeficiency Virus Infections","enrollment":101},{"nctId":"NCT00960622","phase":"PHASE4","title":"Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects","status":"COMPLETED","sponsor":"St. Luke's-Roosevelt Hospital Center","startDate":"2006-08","conditions":"HIV","enrollment":17},{"nctId":"NCT00915655","phase":"PHASE2","title":"A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2009-07","conditions":"HIV-1 Infection","enrollment":12},{"nctId":"NCT00450580","phase":"PHASE3","title":"HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2007-03","conditions":"Infection, Human Immunodeficiency Virus I, HIV-1 Infection","enrollment":212},{"nctId":"NCT00724711","phase":"PHASE4","title":"Safety and Efficacy Study of Switching From Epzicom to Truvada","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":312},{"nctId":"NCT00820118","phase":"PHASE2","title":"Early and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2009-05","conditions":"HIV Infections","enrollment":45},{"nctId":"NCT00772902","phase":"PHASE4","title":"ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-10","conditions":"HIV-1","enrollment":85},{"nctId":"NCT00192634","phase":"PHASE4","title":"A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2005-12","conditions":"HIV Infections","enrollment":357},{"nctId":"NCT00549198","phase":"PHASE4","title":"KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06","conditions":"Infection, Human Immunodeficiency Virus I, HIV Infection","enrollment":392},{"nctId":"NCT00053638","phase":"PHASE3","title":"A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-02","conditions":"HIV Infection","enrollment":345},{"nctId":"NCT00094367","phase":"PHASE3","title":"A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-07","conditions":"HIV Infection","enrollment":900},{"nctId":"NCT00615810","phase":"PHASE4","title":"ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-03","conditions":"HIV Infections","enrollment":159},{"nctId":"NCT00244712","phase":"PHASE4","title":"Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-07","conditions":"HIV Infection","enrollment":688},{"nctId":"NCT00765271","phase":"PHASE1","title":"Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2008-05","conditions":"HIV","enrollment":29},{"nctId":"NCT00001968","phase":"PHASE1","title":"Once-Daily Drug Regimen for HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-01","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":25},{"nctId":"NCT00318123","phase":"PHASE3","title":"Study to Evaluate the Effectiveness of ABC+3TC +EFV in Once-Daily Regimens Versus KLT in Twice-Daily Regimens in Naive HIV Patients","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2004-04","conditions":"HIV Infections","enrollment":126},{"nctId":"NCT00314626","phase":"PHASE3","title":"Antiretroviral Treatment Simplification Study With Efavirenz + Abacavir + 3TC Once Daily","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2004-11","conditions":"HIV Infections","enrollment":99},{"nctId":"NCT00356616","phase":"PHASE4","title":"Immuno-Virological Efficacy of Combination With Trizivir +Tenofovir in Multiresistant HIV Patients","status":"TERMINATED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2005-09","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT00426296","phase":"PHASE4","title":"SHARE: Simple HAART With Abacavir, Reyataz, and Epivir","status":"UNKNOWN","sponsor":"Clinical Alliance for Research & Education - Infectious Diseases, LLC.","startDate":"2006-08","conditions":"HIV Infections, Lipodystrophy","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":37,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ABC: abacavir: Ziagen","3TC: lamivudine: Epivir","ABC+3TC co-formulated: Kivexa"],"phase":"marketed","status":"active","brandName":"Once-daily ABC+3TC","genericName":"Once-daily ABC+3TC","companyName":"Medical Research Council","companyId":"medical-research-council","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABC+3TC is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors (NRTIs) that blocks HIV reverse transcriptase to prevent viral replication. Used for HIV-1 infection (as part of combination antiretroviral therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}